- Home
- NKTX vs LUCD Comparison
NKTX vs LUCD Comparison
Compare NKTX & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTX
- LUCD
- Stock Information
- Founded
- NKTX 2015
- LUCD 2018
- Country
- NKTX United States
- LUCD United States
- Employees
- NKTX N/A
- LUCD N/A
- Industry
- NKTX Biotechnology: Pharmaceutical Preparations
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- NKTX Health Care
- LUCD Health Care
- Exchange
- NKTX Nasdaq
- LUCD Nasdaq
- Market Cap
- NKTX 123.5M
- LUCD 108.0M
- IPO Year
- NKTX 2020
- LUCD 2021
- Fundamental
- Price
- NKTX $2.30
- LUCD $1.18
- Analyst Decision
- NKTX Strong Buy
- LUCD Strong Buy
- Analyst Count
- NKTX 5
- LUCD 5
- Target Price
- NKTX $13.50
- LUCD $3.70
- AVG Volume (30 Days)
- NKTX 1.2M
- LUCD 1.3M
- Earning Date
- NKTX 11-06-2025
- LUCD 11-12-2025
- Dividend Yield
- NKTX N/A
- LUCD N/A
- EPS Growth
- NKTX N/A
- LUCD N/A
- EPS
- NKTX N/A
- LUCD N/A
- Revenue
- NKTX N/A
- LUCD $4,360,000.00
- Revenue This Year
- NKTX N/A
- LUCD $13.90
- Revenue Next Year
- NKTX N/A
- LUCD $163.88
- P/E Ratio
- NKTX N/A
- LUCD N/A
- Revenue Growth
- NKTX N/A
- LUCD 14.74
- 52 Week Low
- NKTX $1.31
- LUCD $0.75
- 52 Week High
- NKTX $4.55
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- NKTX 53.68
- LUCD 54.77
- Support Level
- NKTX $2.11
- LUCD $1.14
- Resistance Level
- NKTX $2.74
- LUCD $1.27
- Average True Range (ATR)
- NKTX 0.18
- LUCD 0.07
- MACD
- NKTX 0.03
- LUCD 0.02
- Stochastic Oscillator
- NKTX 39.58
- LUCD 66.67
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.